@Bigdaddio
My summary would be that the clinical trial is designed in such a way (based on the results of the phase 2 trial) that allows for the maximum probability for success.
The key statistic I would be keeping an eye out for is left ventricular ejection fraction (LVEF). If it's increased significantly in the MPC-150-IM group, then this treatment would be a massive home run.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.005(0.31%) |
Mkt cap ! $2.041B | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.62 | $1.57 | $2.363M | 1.487M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 50250 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.61 | 20216 | 20 |
View Market Depth
| Last trade - 11.11am 08/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |